ERBB2 and breast cancer: The molecular classification of BC has revealed that ERα-positive tumors co-expressing the HER2 receptor (i.e., the luminal B (LumB) BCs) are less sensitive to the ET drugs than the ERα-positive tumors devoid of HER2 (i.e., the luminal A (LumA) BCs).